CTSO Stock, CytoSorbents Corporation Information

MEDASORB TECHNOLOGIES CORPORATION is a publicly traded therapeutic device company that has developed a powerful, patented, blood purification technology that can remove unwanted substances from blood and physiologic fluids to treat a number of diseases. CytoSorb TM , the company s flagship product, was designed as a cytokine filter to reduce potentially deadly cytokine storm in critically ill patients with severe sepsis. CytoSorb s blood compatible polymer beads are highly porous, capturing appropriately sized substances in its pores, while letting larger or smaller substances pass around or through. As blood is pumped through a cartridge of these beads using standard dialysis equipment, cytokines and other toxins are captured by the beads and removed from blood. The purified blood is then returned to the patient. CytoSorb TM has shown preliminary clinical benefit in a small human pilot study treated, control in patients with severe sepsis and is currently being used in an up to patient European Sepsis Trial to treat potentially fatal cytokine storm during severe infection and severe sepsis. CytoSorbents, Inc is the operating subsidiary of MedaSorb Technologies Corporation.